[8-K] OrthoPediatrics Corp. Reports Material Event

Rhea-AI Filing Summary

Resideo Technologies, Inc. (NYSE: REZI) filed an 8-K on 5 Aug 2025 to disclose two matters:

• Item 2.02 – Earnings: The company furnished (not filed) its Q2 2025 earnings press release as Exhibit 99. No financial figures are included in the filing; investors must consult the attached release for revenue, EPS or guidance details. Because the information is furnished, it is not subject to Exchange Act Section 18 liability and will not be incorporated by reference into other SEC documents.
• Item 5.07 – Say-on-Pay Frequency: At the 4 Jun 2025 Annual Meeting, 94.4% of votes favored holding advisory votes on executive compensation annually. On 31 Jul 2025, the Board accepted that preference and confirmed it will continue annual advisory votes going forward.

No other material transactions, financial statements or management changes were reported. Exhibit 104 contains the cover-page Inline XBRL data.

Positive

• Board confirms annual advisory votes, demonstrating responsiveness to 94.4% shareholder support and reinforcing good corporate governance.

Negative

• None.

Insights

Financial Analyst

TL;DR: Procedural 8-K; earnings press release furnished, board aligns with shareholder preference—limited market impact.

The filing is largely administrative. The Q2 2025 earnings details are referenced but not disclosed, so investors must await the press release for quantitative insight. Furnishing rather than filing limits legal exposure. Governance-wise, a 94.4% vote for annual say-on-pay is strong; the Board’s decision to comply maintains shareholder alignment and should be viewed positively, albeit routine. Absent financial metrics or strategic actions, the disclosure is unlikely to affect valuation or trading volumes.

0001425450FALSE00014254502023-03-112023-03-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

______________________

Date of Report (Date of earliest event reported): August 5, 2025

OrthoPediatrics Corp.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

001-38242			26-1761833
(Commission File Number)			(I.R.S. Employer Identification Number)

2850 Frontier Drive Warsaw, Indiana			46582
(Address of principal executive offices)			(Zip Code)

Registrant’s telephone number, including area code: (574) 268-6379

Not Applicable

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.00025 par value per share

KIDS

Nasdaq Global Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 under the Securities Act (17 CFR 230.405) or Rule 12b-2 under the Exchange Act (17 CFR 240.12b-2).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ¨

Item 7.01. Regulation FD Disclosure.

The executive officers of OrthoPediatrics Corp. have several upcoming presentations to representatives of investors and analysts. The officers intend to use the material filed as Exhibit 99.1 herewith, in whole or in part, as part of those presentations.

The information in this Item 7.01, including the information incorporated by reference herein from Exhibit 99.1, is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d)			Exhibits
			Exhibit No.			Description
			99.1			Orthopediatrics Corp. Investor Presentation dated August 2025
			104			Cover Page Interactive Data File (embedded within the Inline XBRL document).

* * * * * *

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			OrthoPediatrics Corp.
Date:   August 5, 2025			By:			/s/ Daniel J. Gerritzen
						Daniel J. Gerritzen, General Counsel and Secretary

- 2 -

FAQ

When did Resideo (REZI) release its Q2 2025 earnings?

The earnings press release was issued on August 5, 2025 and is attached as Exhibit 99.

What items are covered in Resideos August 5, 2025 8-K?

Item 2.02 (Results of Operations – earnings press release) and Item 5.07 (say-on-pay frequency vote outcome).

How did shareholders vote on the frequency of executive compensation advisory votes?

94.4% of shares voted favored conducting the advisory vote annually.

What decision did the Board make regarding future say-on-pay votes?

On July 31, 2025 the Board decided to continue holding the advisory vote on executive compensation every year.

Is the Q2 2025 earnings information considered 'filed' with the SEC?

No. It is furnished under Item 2.02, meaning it is not subject to Section 18 liability and is excluded from other filings by reference.